Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Denise has over 30 years of varying experience in the healthcare arena. In August 2009 she joined The Global Resource for Advancing Cancer Education as one of its first employees. She has grown with the organization and now oversees the operational movement of programs, efficiency, and effectiveness within the organization, as well as the daily processes and functions.
Lung Cancer Video Library - Spanish Language: Video #18 Acquired Resistance to Targeted Therapies: Biology and Different Clinical Patterns
Anonymous
Resistencia adquirida a las terapias dirigidas: Biología y diferentes patrones clínicos.
For our 18th video in the GRACE Spanish Lung Cancer Library, 
Dr. Brian Hunis, Medical Director, Head and Neck Cancer Program, Memorial Cancer Institute, Miami, Florida, joined GRACE to discuss the basics of Lung Cancer for Spanish-speaking patients and caregivers. In this video Dr. Hunis addresses acquired resistance to targeted therapies: biology and different clinical patterns.
TRANSCRIPTS - Spanish and English
Resistencia adquirida a las terapias dirigidas: Biología y diferentes patrones clínicos.
Lamentablemente inclusive en pacientes que tienen la translocación de ALK, eventualmente los pacientes van a desarrollar una resistencia adquirida, por lo cual la medicación con crizotinib no va a funcionar mas.
Por lo general, estos son pacientes que van a tener un prelapso o una recaída en sistema nervioso central o pulmón. Esos son pacientes a los cuales que uno va a considerar terapia de segunda línea o cambiar a quimioterapia.
Acquired resistance to targeted therapies: biology and different clinical patterns.
Unfortunately, even patients with ALK translocation will eventually develop an acquired resistance, resulting in crisotinib not working anymore.
In general, these patients will have a relapse or re-fall in the central nervous system or lung. In these patients, we will consider a second line therapy or change to chemotherapy.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Video
This live virtual event, led by Dr. Andrew Srisuwananukorn on October 25, 2025, brought together top oncologists to share the latest updates in blood cancer treatment. The program featured patient-focused presentations, expert panel discussions, and a real-time Q&A session where attendees could engage directly with specialists.
To watch the complete playlist, click here.
Image
Video
In this video series led by Dr. Siddharth Sheth and recorded on October 27, 2025, a panel of leading oncologists engages in a dynamic and insightful roundtable discussion as they share newly released data, key highlights, and significant developments in head and neck cancer treatment while addressing the most pressing questions, delivered in a concise and easy-to-understand format.
To watch the complete playlist, click here.
Image
Video
In this series, Vernon Sondak, Chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, and Fiorinda Muhaj, MD Anderson Cancer Center, discuss basal and squamous cell carcinoma, including diagnosis, treatment options, and skin cancer prevention.
To watch the complete playlist, click here.
Thanks to Regeneron and Daiichi-Sankyo.
Online Community
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...